within Pharmacolibrary.Drugs.ATC.L;

model L01EE02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.463,
    Cl             = 0.00023000000000000003,
    adminDuration  = 600,
    adminMass      = 60 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.104,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.004033333333333333,
    Tlag           = 22.2,            
    Vdp             = 0.177,
    k12             = 91.6,
    k21             = 91.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EE02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Cobimetinib is an oral, selective inhibitor of MEK1 and MEK2, which are components of the MAPK/ERK pathway. It is primarily used in combination with vemurafenib for the treatment of unresectable or metastatic melanoma with a BRAF V600 mutation. Cobimetinib is approved by the FDA and EMA for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with advanced solid tumors, primarily metastatic melanoma. Data represent population PK results following multiple oral doses.</p><h4>References</h4><ol><li><p>Cheeti, S, et al., &amp; Musib, L (2021). Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug Characteristics. <i>Clinical pharmacology in drug development</i> 10(2) 144–152. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.847&quot;>10.1002/cpdd.847</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32696585/&quot;>https://pubmed.ncbi.nlm.nih.gov/32696585</a></p></li><li><p>Takahashi, RH, et al., &amp; Choo, EF (2017). Absorption, metabolism and excretion of cobimetinib, an oral MEK inhibitor, in rats and dogs. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 47(1) 50–65. DOI:<a href=&quot;https://doi.org/10.3109/00498254.2016.1157645&quot;>10.3109/00498254.2016.1157645</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27055783/&quot;>https://pubmed.ncbi.nlm.nih.gov/27055783</a></p></li><li><p>Takahashi, RH, et al., &amp; Musib, L (2016). Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 44(1) 28–39. DOI:<a href=&quot;https://doi.org/10.1124/dmd.115.066282&quot;>10.1124/dmd.115.066282</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26451002/&quot;>https://pubmed.ncbi.nlm.nih.gov/26451002</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EE02;
